Modern Strategies in Generalized Myasthenia Gravis: Diagnosis, Therapy, and Individualized Care

Generalized myasthenia gravis (gMG) has entered a new era of precision therapy. Once managed primarily through symptomatic and broad immunosuppressive approaches, gMG is now recognized as a heterogeneous autoimmune disorder requiring individualized diagnostic and therapeutic strategies.

This CME/CE symposium provides a comprehensive exploration of the evolving science and clinical management of gMG, integrating insights from pivotal clinical trials and real-world practice. Faculty will review the mechanisms, safety, and efficacy of novel targeted agents, including complement and FcRn inhibitors, and discuss how these therapies can be optimally sequenced and personalized for diverse patient subgroups, such as those with AChR, MuSK, LRP4, or seronegative disease.

Participants will also examine persistent challenges in diagnostic precision, treatment integration, and long-term disease control, including how to balance efficacy, safety, and patient preferences in chronic management. Learners will gain multidisciplinary perspectives to improve care coordination, enhance communication, and align treatment goals with patient-reported outcomes.

This event talks about empowering clinicians to apply evidence-based, patient-centered strategies that advance individualized care and improve the quality of life for patients living with gMG.

Learning Objectives:

• Improve recognition of clinical and serologic subtypes of gMG using broader diagnostic strategies.
• Compare the mechanisms and clinical applications of various therapeutic classes used in gMG management.
• Evaluate safety, efficacy, and patient-specific factors for selecting and sequencing treatment options.
• Apply individualized treatment approaches based on disease subtype, severity, and response history.
• Enhance communication with patients regarding treatment goals, expectations, and long-term management.